Biocompatibility Testing Support System for Medical Devices (Part 1)

As China's medical device industry accelerates, biocompatibility testing—a critical step in ensuring device safety—is receiving increasing attention from the National Medical Products Administration (NMPA).NMPA) and the close attention of relevant regulatory authorities. By establishing a comprehensive testing and evaluation policy framework, China has made significant progress in the field of biological evaluation of medical devices, forming a system based onGB/T 16886andISO 10993A complete framework centered on standards and supported by multi-dimensional policies.

Completeness of the monitoring and evaluation system

The establishment of China's biological evaluation system for medical devices has evolved from single testing to a full lifecycle assessment. Research indicates that biological evaluation has progressed from a mere testing phase to a specialized research activity integrated into design and development inputs, shifting from pre-market evaluation to a comprehensive lifecycle approach. This reflects the modernization of regulatory philosophy.

(I) Comprehensiveness of the Standards System

GB/T 16886The series of standards serves as the core basis for biological evaluation of medical devices in China and is identical to the conversion ofISO 10993Essential content of international standards; the current version alone reaches19a standard, primarily covering the following aspects:

Guideline Standards：GB/T 16886.1"Evaluation and Testing in the Risk Management Process" serves as a guiding principle that establishes the methodological foundation for all biocompatibility assessments, requiring risk evaluations based on the intended use of the medical device, contact site, and duration of contact.

Test Method Standard: Includes cytotoxicity (GB/T 16886.5), genotoxicity, sensitization, skin irritation (GB/T 16886.10blood compatibility, carcinogenicity, reproductive and developmental toxicity, systemic toxicity, etc.16Test items across multiple aspects to ensure the safety of medical device contact with the human body.

Sample Preparation and Material Characterization：GB/T 16886.12Specifies requirements for sample preparation and reference material selection.GB/T 16886.17to19This clarifies material chemical characterization methods, ensuring scientific rigor from the source.

Animal Welfare Requirements：GB/T 16886.2Specifically mandates welfare requirements for animal experiments, reflecting China's efforts to align with international standards in humane experimentation.

(II) Enhancing Technical Review Capabilities

Center for Medical Device Evaluation, National Medical Products Administration (CMD) serves as the core technical support agency, responsible for critical medical device technical review duties.2024End of Year2025During the year, the National Medical Products Administration (NMPA) significantly increased its investment in medical device technical review. It established regional review centers, including branches in the Yangtze River Delta and Greater Bay Area, forming a nationwide review network.

The departmental budget report shows that the National Medical Products Administration is continuously increasing its investments in medical device technical review services and digitalized review and inspection services.2024Total funding for the annual Yangtze River Delta branch review and inspection digitalization service project reaches400tens of thousands of yuan,2025Annual project funding also reached340Over 10,000 yuan, reflecting a strong commitment to building technical capabilities.